• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting

    6/25/25 8:00:00 AM ET
    $ENTX
    $OPK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENTX alert in real time by email

    MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) and Entera Bio Ltd. (NASDAQ:ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected for presentation at the ENDO 2025 annual meeting of the Endocrine Society, taking place July 12-15, 2025 in San Francisco, CA, USA.

    Oral OPK-88006 is being developed pursuant to a collaboration and license agreement between OPKO and Entera whereby the companies are advancing a proprietary novel dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment and as a weekly subcutaneous injection for patients with obesity, metabolic and fibrotic disorders. The oral program combines OPKO's proprietary long-acting oxyntomodulin analog (OPK-88006) and Entera's proprietary N-Tab™ technology.

    "Oral peptides remain rare in metabolic therapy, and having both tablet and injectable formats with our partner OPKO should allow us to tailor induction and maintenance regimens to each patient to optimize outcomes," said Miranda Toledano, Chief Executive Officer of Entera. "Our once-daily tablet may be simpler to titrate and offer tolerability benefits. Our joint program prioritizes durable, sustainable weight loss to help prevent or mitigate comorbidities such as severe fatty liver, sleep apnea, and other metabolic disorders."

    OPKO and Entera expect to file an Investigational New Drug application with the U.S. Food and Drug Administration later this year for both oral OPK-88006 tablet and a weekly injectable variant of the same molecule, which OPKO intends to develop independently. Phase 1 clinical studies are being planned.

    Abstract Title: First-in-Class Oral Dual GLP-1/Glucagon Agonist for Patients with Obesity and Metabolic Disorders: In Vivo Pharmacokinetic and Pharmacodynamic Results

    Presentation Number:  SUN-680

    Session Date/Time: Sunday, July 13, 2025, 12:00 – 01:30 PM Pacific time

    About Entera Bio

    Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N-Tab™) and its pipeline of first-in-class oral peptide programs targeting PTH(1-34), GLP-1 and GLP-2. The Company's most advanced product candidate, EB613 (oral PTH(1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for post-menopausal women with low BMD and high-risk osteoporosis. A placebo controlled, dose ranging Phase 2 study of EB613 tablets (n=161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is preparing to initiate a Phase 3 registrational study for EB613 pursuant to the FDA's qualification of a quantitative BMD endpoint. The EB612 program is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and the first oral GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health. For more information on Entera Bio, visit www.enterabio.com or follow us on LinkedIn, Twitter, Facebook, Instagram.

    About OPKO Health

    OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise, and its novel and proprietary technologies. For more information, visit www.opko.com.

    Cautionary Statement Regarding Forward Looking Statements

    Various statements in this presentation are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this presentation regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward-looking statements. Words such as, but not limited to, "anticipate," "believe," "can," "could," "expect," "estimate," "design," "goal," "intend," "may," "might," "objective," "plan," "predict," "project," "target," "likely," "should," "will," and "would," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.

    Important factors that could cause actual results to differ materially from those reflected in Entera's and OPKO's forward-looking statements include, among others: results of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the anticipated benefits of both the daily tablet and an injectable form; Entera's and OPKO's expectations regarding licensing, business transactions, including OPKO's development efforts should Entera opt-out, and strategic collaborations; and other factors that are described in the "Cautionary Statements Regarding Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of each of Entera's and OPKO's most recent Annual Reports on Form 10-K filed with the SEC, as well as the companies' respective subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance that the actual results or developments anticipated by Entera and OPKO will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera or OPKO, as applicable. Therefore, no assurance can be given that the outcomes stated or implied in such forward-looking statements and estimates will be achieved. Entera and OPKO caution investors not to rely on the forward-looking statements made in this press release. The information in this press release is provided only as of the date of this press release, and neither Entera nor OPKO undertakes any obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

    Contacts:

    Entera Bio

    Miranda Toledano

    Chief Executive Officer

    [email protected]  

    OPKO Health

    Alliance Advisors IR

    Yvonne Briggs, 310-691-7100

    [email protected] 

                      or 

    Bruce Voss, 310-691-7100 

    [email protected]



    Primary Logo

    Get the next $ENTX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ENTX
    $OPK

    CompanyDatePrice TargetRatingAnalyst
    OPKO Health Inc.
    $OPK
    4/25/2025Neutral
    Analyst
    OPKO Health Inc.
    $OPK
    6/29/2023$2.00Mkt Perform → Outperform
    Barrington Research
    OPKO Health Inc.
    $OPK
    12/15/2022$3.00Buy
    H.C. Wainwright
    OPKO Health Inc.
    $OPK
    1/24/2022Outperform → Market Perform
    Barrington Research
    More analyst ratings

    $ENTX
    $OPK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NextPlat Issues Interim CEO Update Shareholder Letter

      COCONUT GROVE, Fla., June 30, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW), NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through eCommerce and retail channels worldwide, today issued the following Interim CEO Update Shareholder Letter: To Our Shareholders: As interim CEO of NextPlat and on behalf of our Board of Directors and management team, I am writing to you to provide an update on our company and the actions being taken to drive the business forward. In the month since the un

      6/30/25 8:01:00 AM ET
      $NXPL
      $OPK
      Telecommunications Equipment
      Telecommunications
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting

      JERUSALEM, June 26, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and proteins replacement therapies, announced that new data exploring the dual actions of EB613 on trabecular and cortical bone was selected for oral presentation at the American Society for Bone and Mineral Research (ASBMR) 2025 Annual Meeting, taking place September 5-8 in Seattle, Washington, USA. EB613 is being developed as the first once-daily oral anabolic (bone forming) PTH(1-34) tablet treatment to support earlier osteoanabolic intervention for postmenopausal women with osteoporosis at high risk for fracture. The Phase 2 study randomized 161 postmenopausal women

      6/26/25 8:00:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium

      MIAMI, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced its participation in the 3rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025. Management will be participating in a fireside discussion moderated by Edward Tentoff, Managing Director, Senior Biotechnology Analyst. Investors can register for the symposium by contacting their Piper Sandler representative. About OPKO Health OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and propriet

      6/25/25 11:00:00 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTX
    $OPK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Analyst initiated coverage on Opko Health

      Analyst initiated coverage of Opko Health with a rating of Neutral

      4/25/25 8:32:28 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Opko Health upgraded by Barrington Research with a new price target

      Barrington Research upgraded Opko Health from Mkt Perform to Outperform and set a new price target of $2.00

      6/29/23 9:11:26 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Opko Health with a new price target

      H.C. Wainwright initiated coverage of Opko Health with a rating of Buy and set a new price target of $3.00

      12/15/22 8:08:28 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTX
    $OPK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO & Chairman Frost Phillip Md Et Al bought $169,712 worth of shares (125,000 units at $1.36) (SEC Form 4)

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      4/10/25 5:07:15 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO & Chairman Frost Phillip Md Et Al bought $184,650 worth of shares (125,000 units at $1.48) (SEC Form 4)

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      4/8/25 5:34:21 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO & Chairman Frost Phillip Md Et Al bought $164,850 worth of shares (100,000 units at $1.65) (SEC Form 4)

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      4/1/25 5:21:45 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTX
    $OPK
    SEC Filings

    See more
    • SEC Form EFFECT filed by Entera Bio Ltd.

      EFFECT - Entera Bio Ltd. (0001638097) (Filer)

      6/9/25 12:15:24 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by Entera Bio Ltd.

      424B3 - Entera Bio Ltd. (0001638097) (Filer)

      6/6/25 4:08:47 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Entera Bio Ltd.

      DEFA14A - Entera Bio Ltd. (0001638097) (Filer)

      6/5/25 4:28:12 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENTX
    $OPK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CEO & Chairman Frost Phillip Md Et Al

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      5/29/25 5:08:32 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Vice Chairman & CTO Hsiao Jane Ph D

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      5/29/25 5:07:08 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Vice Chairman and President Zerhouni Elias A.

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      5/29/25 5:05:24 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTX
    $OPK
    Leadership Updates

    Live Leadership Updates

    See more
    • Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

      JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025. "During Q1 2025, Entera continued to generate intrinsic value with progress across our programs while significantly extending our cash runway into late 2026 via direct investment from marquis investors and our strategic partner, OPKO Health Inc. ("OPKO"). EB613 early mechanistic effects on both trabecular and cortical bone compartments data using 3D-Shaper software analysis was selected for oral presentation out of 1,680 abstracts submit

      5/9/25 4:05:00 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • OPKO Health's ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development

      WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ:OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medical Officer, a newly created position. Dr. Abbadessa has over two decades of experience in drug development, including most recently as Vice President at Sanofi, where he provided executive leadership for advancing oncology assets. "Dr. Abbadessa's deep experience in leading early-stage oncology development makes him the ideal fit to steer development of our multispecific antibodies for cancer and other clinical indications," said Dr. Gary Nabel, co-founder, President and CEO of ModeX Thera

      9/23/24 8:00:00 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

      JERUSALEM, May 15, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company"), a leader in the development of orally delivered peptides and small therapeutic proteins, today announced the appointment of Rachel B Wagman, MD, FACE, FACP, as Key Clinical Advisor and Member of its Scientific Advisory Board. Dr. Wagman brings more than 20 years of metabolic bone disease and women's health research and drug development experience to Entera. She has successfully advanced the development of five molecules, including the osteoporosis products teriparatide (Forteo®), denosumab (Prolia®) and romosozumab (Evenity®) through clinical development, registration, and lifecycle mana

      5/15/24 8:00:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENTX
    $OPK
    Financials

    Live finance-specific insights

    See more
    • OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results

      MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three months ended March 31, 2025. Highlights from the first quarter of 2025 and recent weeks include the following: Signed definitive agreement with Labcorp to sell oncology and related clinical testing assets of BioReference Health (BioReference). The transaction includes the sale of BioReference's laboratory testing businesses focused on oncology and oncology-related clinical testing services for up to $225 million, including $192.5 million payable at closing and up to $32.5 million in an earnout based on performance. BioReference will continue to

      4/30/25 4:05:00 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025

      MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Wednesday, April 30, 2025. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on April 30th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participan

      4/17/25 8:00:00 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results

      MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the fourth quarter of 2024 and recent weeks include the following: Enrollment and dosing underway by Merck in the Phase 1 Epstein-Barr virus (EBV) vaccine trial. Dosing of patients has commenced for the Phase I study (NCT06655324) of an EBV vaccine candidate being developed in collaboration with Merck. The investigational vaccine, based on ModeX's ferritin nanoparticle vaccine platform, is being evaluated for safety and tolerability in up to 200 healthy adults. Commencement of this study triggere

      2/27/25 4:10:15 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTX
    $OPK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Entera Bio Ltd.

      SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

      11/20/24 1:48:55 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by OPKO Health Inc.

      SC 13D/A - OPKO HEALTH, INC. (0000944809) (Subject)

      11/15/24 4:39:33 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by OPKO Health Inc.

      SC 13G - OPKO HEALTH, INC. (0000944809) (Subject)

      11/13/24 4:30:24 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care